Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group

Supportive Care in Cancer

Volumn 16, Issue 1, 2008, Pages 67-74

  Gianni, Lorenzo ^a   Cole, Bernard F ^b,c   Panzini, Ilaria ^a   Snyder, Raymond ^d   Holmberg, Stig B ^e   Byrne, Michael ^f   Crivellari, Diana ^g   Colleoni, Marco ^h   Aebi, Stefan ^i,j   Simoncini, Edda ^k   Pagani, Olivia ^j,l   Castiglione Gertsch, Monica ^m   Price, Karen N ⁿ   Goldhirsch, Aron ^h,l   Coates, Alan S ^m,o   Ravaioli, Alberto ^a  

^a OSPEDALE DEGLI INFERMI   (Italy)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d ST VINCENT S HOSPITAL   (Australia)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^g CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^h EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^k SPEDALI CIVILI   (Italy)

^l ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^m International Breast Cancer Study Group Coordinating Center   (Switzerland)

ⁿ FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^o UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

Adjuvant therapy; Adverse event; Anemia; Breast cancer; Chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HEMOGLOBIN; METHOTREXATE;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; EARLY CANCER; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; LEUKOCYTE COUNT; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; RISK ASSESSMENT; SURGICAL TECHNIQUE; THROMBOCYTE;

ADULT; AGE FACTORS; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; HEMOGLOBINS; HUMANS; INCIDENCE; LEUKOCYTES; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 36949006925     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-007-0295-y     Document Type: Article

References (27)

1. Barrett-Lee PJ, Ludwig H, Birgegard G, Bokemeyer C, Gascon P, Kosmidis PA, Krzakowski M, Nortier JW, Kongable G, Schneider M, Schrijvers D, Van Belle SJ (2006) European cancer anaemia survey advisory board and participating centers. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology 70:34-48
2. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennett CL, Langensiepen S, Hyde C, Engert A (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708-714
3. Bron D, Meuleman N, Mascaux C (2001) Biological basis of anemia. Semin Oncol 28(suppl 8):S1-S6
4. Cella D (1998) Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25(suppl 7):S43-S46
5. Chang J, Couture F, Young S, McWatters KL, Lau CY (2005) Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 23:2597-2605
6. Coiffier B, Guastalla JP, Pujade-Lauraine E, Bastit P (2001) Anemia Study Group Anemia Study Group. Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer 37:1617-1623
7. Couture F, Turner AR, Melosky B, Xiu L, Plante RK, Lau CY, Quirt I (2005) Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management. Oncologist 10:63-71
8. Demetri GD, Kris M, Wade J, Degos L, Cella D (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16:3412-3425
9. Denison U, Baumann J, Peters-Engl C, Samonigg H, Krippl P, Lang A, Obermair A, Wagner H, Sevelda P (2003) Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy. Breast Cancer Res Treat 79:347-353
10. Dranitsaris G, Clemons M, Verma S, Lau C, Vincent M (2005) Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction model. Lancet Oncol 6:856-863
11. Du XL, Osborne C, Goodwin JS (2002) Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 20:4636-4642
12. Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91:1616-1634
13. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW (2006) Erythropoietin biology in cancer. Clin Cancer Res 12:332-339
14. Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC (2006) Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1108-1117
15. Henke M, Mattern D, Pepe M, Bezay C, Weissenberger C, Werner M, Pajonk F (2006) Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 24:4708-4713
16. International Breast Cancer Study Group (2004) Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol 15:1749-1759
17. International Breast Cancer Study Group (2006) Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 24:1332-1341
18. Kirshner J, Hatch M, Hennessy DD, Fridman M, Tannous RE (2004) Anemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy. Oncologist 9:25-32
19. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23:5960-5972
20. Littlewood TJ, Zagari M, Pallister C, Perkins A (2003) Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. Oncologist 8:99-107
21. National Cancer Institute. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events v3.0 (CTCAE), 8/2006 update. http://ctep.cancer.gov/reporting/ctc_v30.html
22. National Comprehensive Cancer Network. National Comprehensive Cancer Network: clinical practice guidelines in oncology: senior adult oncology-Version 1.2005. http://www.nccn.org/professionals/physician_gls/PDF/senior.pdf
23. Pivot X, Guardiola E, Etienne M, Thyss A, Foa C, Otto J, Schneider M, Magne N, Bensadoun RJ, Renee N, Milano G (2000) An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia. Eur J Cancer 36:852-857
24. Ray-Coquard I, Le Cesne A, Rubio MT, Mermet J, Maugard C, Ravaud A, Chevreau C, Sebban C, Bachelot T, Biron P, Blay JY (1999) Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol 17:2840-2846
25. Tanvetyanon T, Choudhury AM (2006) Severity, risk factors, and physician practices in the management of anemia during concurrent chemoradiation for head and neck carcinoma. Cancer 106:1554-1559
26. Tas F, Eralp Y, Basaran M, Sakar B, Alici S, Argon A, Bulutlar G, Camlica H, Aydiner A, Topuz E (2002) Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol 25:371-379
27. Vincent M, Dranitsaris G, Verma S, Lau C, Gascon P, Van Belle S, Ludwig H (2007) The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy. Support Care Cancer 15(3):265-272